Maria Varela, MD, PhD | Authors


Survival Benefit Confirmed in Real-Life Analysis of Second-Line Regorafenib in HCC

December 06, 2019

María Varela, MD, PhD, discusses the findings from a real-life analysis to confirm the benefit of regorafenib as treatment of patients with hepatocellular carcinoma who have progressed on prior sorafenib. Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.